262 related articles for article (PubMed ID: 25648097)
21. Reversible pre-capillary pulmonary hypertension due to dasatinib.
Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
[TBL] [Abstract][Full Text] [Related]
22. [Mixed connective tissue disease with pulmonary hypertension developing in a chronic myeloid leukemia patient on dasatinib treatment].
Watanuki S; Kikuchi T; Toyama T; Abe R; Nakayama H; Karigane D; Shimizu T; Kikuchi J; Matsumoto K; Yasuoka H; Kataoka M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(2):174-177. PubMed ID: 29515069
[TBL] [Abstract][Full Text] [Related]
23. Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension.
Toya T; Nagatomo Y; Kagami K; Yukino M; Yasuda R; Namba T; Ido Y; Kobayashi S; Masaki N; Yada H; Kimura F; Adachi T
Int J Cardiovasc Imaging; 2019 Aug; 35(8):1435-1442. PubMed ID: 30715668
[TBL] [Abstract][Full Text] [Related]
24. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Maral S; Bakanay SM; Kucuksahin O; Dilek I
J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
26. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.
Kostos L; Burbury K; Srivastava G; Prince HM
Platelets; 2015; 26(8):809-11. PubMed ID: 26029798
[TBL] [Abstract][Full Text] [Related]
28. Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose.
Kubota K; Imai Y; Oh I; Ueno S; Kanda Y; Kario K
Intern Med; 2022 Aug; 61(15):2263-2271. PubMed ID: 35022343
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia.
Inoue H; Taji H; Yamada K; Iriyama C; Saito T; Kato H; Yanada M; Yamamoto K; Matsukawa N
Intern Med; 2020 Oct; 59(19):2419-2421. PubMed ID: 32611965
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.
Ishida T; Akagawa N; Miyata T; Tominaga N; Iizuka T; Higashihara M; Suzuki T; Miyazaki K
Int J Hematol; 2018 Mar; 107(3):373-377. PubMed ID: 29027647
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
Taçoy G; Çengel A; Özkurt ZN; Türkoğlu S
Turk Kardiyol Dern Ars; 2015 Jan; 43(1):78-81. PubMed ID: 25655855
[TBL] [Abstract][Full Text] [Related]
34. [Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia].
Yang S; Qin YZ; Lai YY; Shi HX; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1013-1019. PubMed ID: 33445849
[No Abstract] [Full Text] [Related]
35. Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?
Saydan B; Özmen D; Eşkazan AE
Expert Rev Hematol; 2024 Jul; 17(7):275-277. PubMed ID: 38888284
[No Abstract] [Full Text] [Related]
36. Dasatinib-induced Pulmonary Hypertension.
Tamura Y; Tamura Y
Intern Med; 2022 Aug; 61(15):2245-2246. PubMed ID: 35110497
[No Abstract] [Full Text] [Related]
37. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Orlandi EM; Rocca B; Pazzano AS; Ghio S
Leuk Res; 2012 Jan; 36(1):e4-6. PubMed ID: 21890201
[No Abstract] [Full Text] [Related]
38. Dasatinib-induced pulmonary arterial hypertension.
Özgür Yurttaş N; Eşkazan AE
Br J Clin Pharmacol; 2018 May; 84(5):835-845. PubMed ID: 29334406
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature.
Hickman K; Diaz E; Graham R; Adams R; Ngwube A
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e665-e667. PubMed ID: 31688632
[TBL] [Abstract][Full Text] [Related]
40. [Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure].
Santos-Macías JE; Baez de la Fuente E; Salas-Delgado A
Gac Med Mex; 2016; 152(3):334-8. PubMed ID: 27335188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
